CHELSEA MASHBURN: Open Payments
NPI 1962944355 · DOTHAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$460 in 22 payments from 10 companies in 2025. Trend: 2023 $822 · 2024 $917 · 2025 $460
Food & beverage: $460
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $90 |
| ABBVIE INC. | 4 | $85 |
| PFIZER INC. | 3 | $57 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
| AstraZeneca Pharmaceuticals LP | 2 | $44 |
| Novo Nordisk Inc | 2 | $39 |
| Lilly USA, LLC | 2 | $37 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $19 |
| Exact Sciences Corporation | 1 | $16 |
Products named: XIFAXAN, NURTEC ODT, CAPLYTA, MOUNJARO, VRAYLAR, UBRELVY, FARXIGA, QULIPTA.
Industry payments across AL — which companies pay providers there.
